57,804 Shares in MediWound Ltd. $MDWD Purchased by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd acquired a new stake in MediWound Ltd. (NASDAQ:MDWD) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 57,804 shares of the biopharmaceutical company’s stock, valued at approximately $1,042,000.

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in shares of MediWound during the third quarter worth about $194,000. Envestnet Asset Management Inc. purchased a new stake in MediWound during the 3rd quarter worth $243,000. Meitav Investment House Ltd. lifted its position in MediWound by 825.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after acquiring an additional 260,116 shares in the last quarter. MGO One Seven LLC boosted its position in MediWound by 82.6% in the 3rd quarter. MGO One Seven LLC now owns 22,209 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 10,047 shares during the last quarter. Finally, Sheets Smith Investment Management purchased a new position in MediWound in the third quarter valued at about $362,000. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MDWD shares. Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MediWound has an average rating of “Hold” and an average target price of $31.67.

MediWound Stock Performance

MDWD opened at $17.30 on Friday. The company has a market cap of $221.61 million, a PE ratio of -9.11 and a beta of 0.13. The stock has a 50-day moving average of $17.84 and a 200-day moving average of $17.90. MediWound Ltd. has a 52-week low of $14.14 and a 52-week high of $22.50.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.